• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

South Korea Pharma-Biotech Space Predicted $23.2bn by 2022

Article

Pharmaceutical Executive

South Korea has plans to invest over $1.7 billion (US) into its biotech and biopharma segments over the next five years. The pharmaceutical market in South Korea is predicted to increase to $23.2 billion (US), an increase from the $19.5 billion (US) in 2018, according to Global Data.

GlobalData’s research reveals that a number of deals within key therapy areas in South Korea’s pharma/biotech space have followed an increased trend between 2015 and 2018. The potential for biopharmaceutical development is very high in these areas, which include oncology, gastroenterology and immunology.

 

Related Videos
Related Content